1. Home
  2. MTA vs DCTH Comparison

MTA vs DCTH Comparison

Compare MTA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

N/A

Current Price

$9.82

Market Cap

636.3M

Sector

N/A

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$16.35

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MTA
DCTH
Founded
1983
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.3M
578.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
MTA
DCTH
Price
$9.82
$16.35
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$9.00
$22.00
AVG Volume (30 Days)
579.7K
702.1K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
$81.63
$24.54
Revenue Next Year
$62.44
$33.15
P/E Ratio
N/A
$410.00
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$8.12
52 Week High
$11.60
$17.42

Technical Indicators

Market Signals
Indicator
MTA
DCTH
Relative Strength Index (RSI) 56.81 60.29
Support Level $6.35 $9.98
Resistance Level $11.60 $17.42
Average True Range (ATR) 0.50 0.45
MACD -0.13 -0.19
Stochastic Oscillator 43.17 34.62

Price Performance

Historical Comparison
MTA
DCTH

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA, with the majority generated from Brazil.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: